Patents by Inventor Scott D. Cormack

Scott D. Cormack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Clusterin Antisense Therapy for Treatment of Cancer
    Publication number: 20160168577
    Abstract: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
    Type: Application
    Filed: November 4, 2015
    Publication date: June 16, 2016
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Martin E. Gleave, Scott D. Cormack
  • Clusterin antisense therapy for treatment of cancer
    Patent number: 9200285
    Abstract: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: December 1, 2015
    Assignee: The University of British Columbia
    Inventors: Martin E. Gleave, Scott D. Cormack
  • Clusterin Antisense Therapy for Treatment of Cancer
    Publication number: 20140242192
    Abstract: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 28, 2014
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Martin E. Gleave, Scott D. Cormack
  • Clusterin antisense therapy for treatment of cancer
    Patent number: 8710020
    Abstract: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: April 29, 2014
    Assignee: The University of British Columbia
    Inventors: Martin E. Gleave, Scott D. Cormack
  • Clusterin Antisense Therapy for Treatment of Cancer
    Publication number: 20080119425
    Abstract: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering chemotherapeutic agent or agents, radiotherapy, and/or hormone ablation therapy. The invention also encompasses pharmaceutical compositions formulated to provide a dosage of 40 to 640 mg, and use of antisense in formulating a medicament.
    Type: Application
    Filed: September 6, 2006
    Publication date: May 22, 2008
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Martin E. Gleave, Scott D. Cormack